IP Library Granted Patent US 8,629,240
Granted Patent B2
US 8,629,240 · App. 13/260,676 · Granted Jan 14, 2014

Peptide ligands for clusterin and uses thereof

Inventors: Rana Filfil (Kanata, CA); Dmitri Tolkatchev (La Prairie, CA); Feng Ni (Pierrefonds, CA); Maureen D. O'Connor-McCourt (Beaconsfield, CA); Anne E. G. Lenferink (Lorraine, CA)
Assignee: National Research Council of Canada
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,629,240
App. No.
13/260,676
Granted
Jan 14, 2014
Kind
B2
Abstract

Peptides are disclosed that are useful for molecular imaging or diagnosis of a disease state, such as cancer, in which clusterin is upregulated.

Claims (19)

1. An isolated or a synthesized peptide comprising the amino acid sequence as set forth in SEQ ID NO:1 or SEQ ID NO:2 or an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2.

2. The isolated or synthesized peptide according to claim 1 linked to a cargo molecule.

3. The isolated or synthesized peptide according to claim 2 , wherein the cargo molecule comprises an enzyme, an imaging moiety, a radioisotope or a cytotoxic agent.

4. The isolated or synthesized peptide according to claim 2 , wherein the cargo molecule comprises an imaging moiety.

5. The isolated or synthesized peptide according to claim 4 , wherein the imaging moiety comprises a radiolabel, a fluorophore, a near infrared fluorochrome or a magnetic nanoparticle.

6. A method of molecular imaging, diagnosis of a disease state in which clusterin is upregulated or treatment of a disease state in which clusterin is upregulated, the method comprising administering peptide having an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO.:1 or SEQ ID NO.:2 to a subject in need of the imaging, diagnosis or treatment.

7. The method according to claim 6 further comprises molecular imaging of a tumor.

8. The method according to claim 7 , wherein the molecular imaging is optical imaging, positron emission tomography, single photon emission computed tomography or magnetic resonance imaging.

9. The method according to claim 6 , wherein the disease state is cancer.

10. A method of imaging a tumor comprising administering to a subject, a peptide comprising the amino acid sequence as set forth in SEQ ID NO.:1 or SEQ ID NO.:2 or an amino acid sequence substantially at least 80% identical to the amino acid sequence set forth in SEQ ID NO.:1 or SEQ ID NO.:2 linked to a cargo molecule, and detecting the imaging moiety in the subject.

11. An isolated or synthesized peptide comprising one, two or three conservative amino acid substitutions in the amino acid sec uence set forth in SEQ ID NO:1 or SEQ ID NO:2.

12. The isolated or synthesized peptide according to claim 1 , comprising the amino acid sequence set forth in SEQ ID NO.:4.

13. The isolated or synthesized peptide according to claim 1 , wherein the amino acid sequence has 85% sequence identity to SEQ ID NO:1 or SEQ ID NO:2.

14. The isolated or synthesized peptide according to claim 1 , wherein the amino acid sequence has 90% sequence identity to SEQ ID NO:1 or SEQ ID NO:2.

15. The isolated or synthesized peptide according to claim 1 , wherein the amino acid sequence has 95% sequence identity to SEQ ID NO:1 or SEQ ID NO:2.

16. The isolated or synthesized peptide according to claim 1 , wherein the amino acid sequence has 100% sequence identity to SEQ ID NO:1 or SEQ ID NO:2.

17. A method of detecting tumor cells comprising administering to a subject in need thereof, an agent including a peptide comprising an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO.:1 or SEQ ID NO.:2 linked to a cargo molecule, and detecting the agent, wherein said peptide is able to specifically bind clusterin.

18. The method of claim 17 , wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2 or an amino acid sequence substantially identical thereto and the cargo molecule comprises an imaging moiety.

19. The method of claim 17 , wherein the peptide consists in the amino acid sequence set forth in SEQ ID NO: 1 and the cargo molecule comprises an imaging moiety.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2023
From: JOINT-STOCK COMPANY GENERIUM
To: ALETHIA BIOTHERAPEUTICS INC.
Reel/Frame 065622/0749 →
LICENSE Recorded Mar 25, 2015
From: NATIONAL RESEARCH COUNCIL OF CANADA
To: ALETHIA BIOTHERAPEUTICS INC.
Reel/Frame 035251/0608 →
DEED OF HYPOTHEC ON SPECIFIC UNIVERSALITIES OF MOVABLE PROPERTY Recorded Jan 10, 2014
From: ALETHIA BIOTHERAPEUTICS INC./ALETHIA BIOTHERAPEUTIQUES INC.
To: IBC GENERIUM LLC
Reel/Frame 031968/0937 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2011
From: FILFIL, RANA; TOLKATCHEV, DMITRI; NI, FENG; O'CONNOR-MCCOURT, MAUREEN D.; LENFERINK, ANNE E.G.
To: NATIONAL RESEARCH COUNCIL OF CANADA
Reel/Frame 027318/0970 →
Continuity (2)
Provisional Application 61202910 · Apr 17, 2009
Related Publication 20120121507A1 · May 17, 2012